Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2566)

ANNOUNCEMENT IN RELATION TO PUBLIC FLOAT

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the "**Company**") pursuant to Rule 19A.28E(1) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The board (the "**Board**") of directors (the "**Directors**") of the Company announced that, as at the date of this announcement, the public float of the Company is approximately 22.22%, which has fallen below 25.0% of the total issued share of the Company (the "**Shares**") held by the public (the "**Minimum Prescribed Percentage**") as prescribed by Rule 19A.28B of the Listing Rules.

The shortfall in the public float of the Company is a result of the recent repurchases of H shares of the Company under the repurchase mandate granted by the shareholders of the Company (the "**Shareholders**") to the Board at the annual general meeting of the Company held on June 11, 2025, which turned one of the public Shareholder into a substantial Shareholder as defined under the Listing Rules.

To the best knowledge, information and belief of the Directors, as at the date of this announcement, the Company's shareholding structure is as follows:

Shareholders	Number of H Shares	Number of unlisted Shares	Number of total Shares	Approximate percentage of the total issued Shares (excluding the treasury Shares)
Substantial Shareholders				
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司)	12,636,136	29,484,317	42,120,453	17.44%
Hangzhou Huasheng Pharmaceutical Group Co., Ltd. (杭州華昇醫藥集團有限公司)	6,499,630	25,998,521	32,498,151	13.46%
CORPORACION QUIMICO-FARMACEUTICA ESTEVE, SOCIEDAD ANóNIMA	6,000,000	24,000,000	30,000,000	12.42%
Zhejiang Wangxin Technology Venture Capital Co., Ltd. (浙江網新科技創投有限公司)	12,256,888	12,256,887	24,513,775	10.15%
Shareholder Controlled by Director				
Hangzhou Nanbeiju Enterprise Management Partnership (Limited Partnership) (杭州南北聚企業管理合夥企業(有限合夥)	1,760,073	3,285,425	5,045,498	2.09%
Other Shareholder Excluded from the Public				
Heda Jinyuan (HK) Co., Limited (和達金源(香港)有限公司)	12,400,400	–	12,400,400	5.13%
Shareholders of Unlisted Shares				
Hangzhou Investment Holdings Co., Ltd. (杭州市金融投資集團有限公司)	–	17,429,338	17,429,338	7.22%
Li Bangliang (李邦良)	–	2,333,184	2,333,184	0.97%
Other Shareholders Holding Unlisted Shares	–	21,514,343	21,514,343	8.91%
Subtotal	51,553,127	136,302,015	187,855,142	77.78%
Public Shareholders	53,661,258	–	53,661,258	22.22%
Total	105,214,385	136,302,015	241,516,400	100%

The Company is considering measures to restore the public float of the Company to the Minimum Prescribed Percentage in accordance with the Listing Rules, including but not limited to (i) implementing the 2026 share award scheme of the Company by way of issuance of new H Shares (including the transfer of treasury Shares); (ii) implementing the H Share full circulation as approved by the Shareholders on the extraordinary general meeting of the Company held on December 22, 2025; and (iii) increasing the capital base of public Shareholders through issuance of new H Shares.

The Company expected to restore the public float of the Company within six months from the date of this announcement, subject to Board approval, regulatory approvals and market conditions. The Company will continue to monitor the issue of insufficient public float and further announcement(s) will be made on a monthly basis to update the Shareholders and potential investors on the status of the public float until the Company has restored its public float in compliance with the Listing Rules.

In addition, the Company will implement the following remedial measures to prevent the recurrence of similar incidents and to establish an ongoing monitoring mechanism for its public float:

(a) reviewing all the disclosure of interests forms relating to the Shares on the Stock Exchange's website on a monthly basis; and

(b) reviewing the monthly report prepared by the Company's share registrar for identifying the substantial Shareholders named on the register of members of the Company on a monthly basis.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, March 5, 2026

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.